Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) by 23.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 562,770 shares of the company’s stock after purchasing an additional 105,082 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.95% of Harmony Biosciences worth $24,924,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in HRMY. JPMorgan Chase & Co. boosted its position in shares of Harmony Biosciences by 13.5% in the 1st quarter. JPMorgan Chase & Co. now owns 25,343 shares of the company’s stock valued at $1,234,000 after purchasing an additional 3,017 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Harmony Biosciences by 9.0% during the first quarter. Bank of New York Mellon Corp now owns 217,304 shares of the company’s stock worth $10,572,000 after purchasing an additional 17,893 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Harmony Biosciences by 19.1% during the first quarter. Citigroup Inc. now owns 25,172 shares of the company’s stock worth $1,225,000 after purchasing an additional 4,030 shares during the period. Acadian Asset Management LLC grew its position in Harmony Biosciences by 69.7% in the 1st quarter. Acadian Asset Management LLC now owns 3,367 shares of the company’s stock valued at $163,000 after buying an additional 1,383 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in Harmony Biosciences by 46.7% in the 1st quarter. MetLife Investment Management LLC now owns 13,697 shares of the company’s stock valued at $666,000 after buying an additional 4,360 shares during the period. 84.76% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Andreas Wicki sold 77,853 shares of the business’s stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $61.23, for a total value of $4,766,939.19. Following the sale, the director now directly owns 2,176,784 shares in the company, valued at approximately $133,284,484.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Andreas Wicki sold 77,853 shares of the business’s stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $61.23, for a total value of $4,766,939.19. Following the sale, the director now directly owns 2,176,784 shares in the company, valued at approximately $133,284,484.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jack Nielsen sold 64,026 shares of the business’s stock in a transaction dated Wednesday, December 7th. The stock was sold at an average price of $60.35, for a total transaction of $3,863,969.10. Following the completion of the sale, the director now owns 2,620,583 shares in the company, valued at $158,152,184.05. The disclosure for this sale can be found here. Insiders have sold 174,247 shares of company stock worth $10,579,966 in the last three months. Corporate insiders own 34.70% of the company’s stock.

Harmony Biosciences Stock Performance

NASDAQ:HRMY opened at $43.24 on Friday. The company has a quick ratio of 5.02, a current ratio of 5.07 and a debt-to-equity ratio of 0.47. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $33.04 and a fifty-two week high of $62.08. The stock has a market cap of $2.58 billion, a PE ratio of 14.56 and a beta of 0.55. The firm’s fifty day simple moving average is $48.93 and its 200-day simple moving average is $50.61.

Wall Street Analyst Weigh In

HRMY has been the topic of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 21st. Mizuho dropped their price objective on shares of Harmony Biosciences from $70.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 22nd. Piper Sandler boosted their price objective on shares of Harmony Biosciences from $62.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, January 4th. TheStreet cut shares of Harmony Biosciences from a “b-” rating to a “c” rating in a research note on Tuesday, February 21st. Finally, The Goldman Sachs Group dropped their price objective on shares of Harmony Biosciences from $49.00 to $43.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $61.89.

About Harmony Biosciences

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.